EAM
IONS icon

Exome Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Exome Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.26M Sell
110,064
-6,451
-6% -$509K 4.27% 4
2025
Q4 		$9.22M Sell
116,515
-14,501
-11% -$1.09M 4.41% 4
2025
Q3 		$8.57M Buy
131,016
+9,900
+8% +$483K 5.19% 1
2025
Q2 		$4.79M Sell
121,116
-14,500
-11% -$475K 3.56% 5
2025
Q1 		$4.09M Buy
135,616
+74,249
+121% +$2.43M 3.64% 7
2024
Q4 		$2.15M Buy
+61,367
New +$2.29M 1.61% 27

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exome Asset Management's IONS Position: Q1 2026 in Review

Exome Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 5.5% in Q1 2026, selling an estimated $509K and leaving 110,064 shares worth $8.26M. The position accounts for 4.27% of the portfolio, ranked #4.

Exome Asset Management first reported a position in IONS in Q4 2024 and has held it in 6 quarters since. The position peaked at $9.22M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Exome Asset Management held 110,064 shares of Ionis Pharmaceuticals worth $8.26M as of Q1 2026.
  • Exome Asset Management sold 6,451 Ionis Pharmaceuticals shares in Q1 2026, an estimated $509K.
  • Ionis Pharmaceuticals made up 4.27% of Exome Asset Management's portfolio in Q1 2026, its #4 holding.
  • Exome Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Exome Asset Management's Ionis Pharmaceuticals position peaked at $9.22M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Exome Asset Management's 13F filing for Q1 2026, filed 15 May 2026.